WallStreetZenWallStreetZen

NASDAQ: CYCN
Cyclerion Therapeutics Inc Stock Forecast, Predictions & Price Target

Open Broker Account

Analyst price target for CYCN

Based on 2 analysts offering 12 month price targets for Cyclerion Therapeutics Inc.
Min Forecast
$4.00+356.62%
Avg Forecast
$9.00+927.4%
Max Forecast
$14.00+1,498.17%

Should I buy or sell CYCN stock?

Based on 2 analysts offering ratings for Cyclerion Therapeutics Inc.
Strong Buy
Strong Buy
2 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their CYCN stock forecasts and price targets.

Forecast return on equity

Is CYCN forecast to generate an efficient return?
Company
-255.32%
Industry
-5.6%
Market
47.24%
CYCN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CYCN forecast to generate an efficient return on assets?
Company
-168.4%
Industry
-5.38%
CYCN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CYCN earnings per share forecast

What is CYCN's earnings per share in the next 2 years based on estimates from 2 analysts?
Avg 1 year Forecast
-$1.15
Avg 2 year Forecast
-$0.97

CYCN revenue forecast

What is CYCN's revenue in the next 2 years based on estimates from 1 analyst?
Avg 1 year Forecast
$1.6M+5.1%
Avg 2 year Forecast
$2.2M+41.94%
CYCN's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CYCN revenue growth forecast

How is CYCN forecast to perform vs Biotechnology companies and vs the US market?
Company
5.1%
Industry
33.41%
Market
5.47%
CYCN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CYCN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CYCN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CYCN$0.88$9.00+927.40%Strong Buy
AVRO$0.87$4.75+444.72%Buy
ACXP$3.30$12.00+263.64%Strong Buy
COEP$1.95N/AN/A
UPC$1.74N/AN/A

Cyclerion Therapeutics Stock Forecast FAQ

Is Cyclerion Therapeutics Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: CYCN) stock is to Strong Buy CYCN stock.

Out of 2 analysts, 2 (100%) are recommending CYCN as a Strong Buy, 0 (0%) are recommending CYCN as a Buy, 0 (0%) are recommending CYCN as a Hold, 0 (0%) are recommending CYCN as a Sell, and 0 (0%) are recommending CYCN as a Strong Sell.

If you're new to stock investing, here's how to buy Cyclerion Therapeutics stock.

What is CYCN's earnings growth forecast for 2022-2023?

(NASDAQ: CYCN) Cyclerion Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 9.45%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 70.56%.

Cyclerion Therapeutics's earnings in 2022 is -$47,637,000.On average, 2 Wall Street analysts forecast CYCN's earnings for 2022 to be -$50,018,312, with the lowest CYCN earnings forecast at -$50,453,253, and the highest CYCN earnings forecast at -$49,583,370.

In 2023, CYCN is forecast to generate -$42,189,358 in earnings, with the lowest earnings forecast at -$54,802,672 and the highest earnings forecast at -$29,141,103.

What is CYCN's revenue growth forecast for 2022-2023?

(NASDAQ: CYCN) Cyclerion Therapeutics's forecast annual revenue growth rate of 5.1% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.41%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 5.47%.

Cyclerion Therapeutics's revenue in 2022 is $1,550,000.On average, 1 Wall Street analysts forecast CYCN's revenue for 2022 to be $70,852,026, with the lowest CYCN revenue forecast at $70,852,026, and the highest CYCN revenue forecast at $70,852,026.

In 2023, CYCN is forecast to generate $95,687,205 in revenue, with the lowest revenue forecast at $95,687,205 and the highest revenue forecast at $95,687,205.

What is CYCN's forecast return on assets (ROA) for 2022-2023?

(NASDAQ: CYCN) forecast ROA is -168.4%, which is lower than the forecast US Biotechnology industry average of -5.38%.

What is CYCN's Price Target?

According to 2 Wall Street analysts that have issued a 1 year CYCN price target, the average CYCN price target is $9.00, with the highest CYCN stock price forecast at $14.00 and the lowest CYCN stock price forecast at $4.00.

On average, Wall Street analysts predict that Cyclerion Therapeutics's share price could reach $9.00 by Aug 18, 2023. The average Cyclerion Therapeutics stock price prediction forecasts a potential upside of 927.4% from the current CYCN share price of $0.88.

What is CYCN's Earnings Per Share (EPS) forecast for 2022-2023?

(NASDAQ: CYCN) Cyclerion Therapeutics's current Earnings Per Share (EPS) is -$1.09. On average, analysts forecast that CYCN's EPS will be -$1.15 for 2022, with the lowest EPS forecast at -$1.16, and the highest EPS forecast at -$1.14. In 2023, CYCN's EPS is forecast to hit -$0.97 (min: -$1.26, max: -$0.67).

What is CYCN's forecast return on equity (ROE) for 2022-2023?

(NASDAQ: CYCN) forecast ROE is -255.32%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.